UK Markets close in 6 hrs 51 mins
  • FTSE 100

    5,602.87
    +20.07 (+0.36%)
     
  • FTSE 250

    17,302.36
    +53.45 (+0.31%)
     
  • AIM

    949.74
    +0.66 (+0.07%)
     
  • GBP/EUR

    1.1089
    +0.0037 (+0.33%)
     
  • GBP/USD

    1.3009
    +0.0022 (+0.1665%)
     
  • BTC-GBP

    10,111.91
    -22.23 (-0.22%)
     
  • CMC Crypto 200

    260.29
    -12.40 (-4.55%)
     
  • S&P 500

    3,271.03
    -119.65 (-3.53%)
     
  • DOW

    26,519.95
    -943.25 (-3.43%)
     
  • CRUDE OIL

    36.57
    -0.82 (-2.19%)
     
  • GOLD FUTURES

    1,880.30
    +1.10 (+0.06%)
     
  • NIKKEI 225

    23,331.94
    -86.57 (-0.37%)
     
  • HANG SENG

    24,586.60
    -122.20 (-0.49%)
     
  • DAX

    11,636.13
    +75.62 (+0.65%)
     
  • CAC 40

    4,584.53
    +13.41 (+0.29%)
     

GSK executive wary of human challenge trials for COVID-19 vaccine

·1-min read
FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in London
FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in London

(Reuters) - GlaxoSmithKline Plc <GSK.L> executive Thomas Breuer said on Tuesday he has "reservations" against human challenge trials as a tool for determining the effectiveness of COVID-19 vaccine candidates without a therapy for the infection.

The British government said last week it was working with partners on the potential for "human challenge" trials, in which volunteers are deliberately infected after receiving an experimental inoculation.

"Yes, younger people are far less likely to observe a severe disease, but it's a little bit of a lottery.....so I have reservations in the current context," Breuer, the British group's chief medical officer for vaccines, said at the World Vaccines Congress Washington.

(Reporting by Manojna Maddipatla in Bengalurul; Editing by Shinjini Ganguli)